Dr. Huang Xiaojun

Chief Physician; Professor; Doctoral Supervisor; Academician of the Chinese Academy of Engineering; Director of Peking University Institute of Hematology; Director of National Clinical Research Center for Hematologic Disease

Creator of the internationally acclaimed "Beijing Protocol" for haplo-identical (half-matched) bone marrow transplantation, which improved patient survival rates from approximately 20% to 70%; performed the world's first T-cell modified haplo-identical transplant in 2000; the Beijing Protocol now covers 95% of haplo-identical transplants in China and over 50% worldwide, and has been adopted in Italy, Israel, France, Japan, South Korea, and Thailand; the protocol is included in international hematology textbooks; elected Academician of the Chinese Academy of Engineering in 2023; recommended by World Marrow Transplant Association president as a reliable approach for patients lacking matched donors

Dr. Huang is the world authority on haplo-identical transplant for leukemia patients who lack fully matched donors. International patients should contact the Peking University People's Hospital international medical service with complete bone marrow biopsy, cytogenetics, molecular testing, and HLA typing reports. Wait times can be significant due to extremely high demand.

Research this doctor's background on trusted platforms.

Results are automated searches and may include other individuals with similar names.